title: Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women.
abstract: OBJECTIVE
  Orlistat and metformin are the currently used drugs for weight loss. We aimed to compare the effect of orlistat and orlistat plus metformin combination therapy on weight loss and insulin resistance in obese women.
  
  
  METHODS
  In all, 57 obese women (body mass index >/=30 kg/m(2) and normal glucose tolerance) were included. All subjects took the same content and caloric diet therapy during the study. After a month of diet period, each individual was randomly assigned to receive 360 mg orlistat per day (group 1; n=30) or 360 mg orlistat plus 1700 mg metformin per day (group 2; n=27) during the next 3 months. Body weight and insulin resistance by the homeostasis model assessment model (HOMA-IR) was measured at baseline, first month and fourth month.
  
  
  RESULTS
  The mean weight loss in groups 1 and 2 was 1.36+/-0.8 kg (1.4+/-0.7%) and 1.11+/-0.7 kg (1.1+/-0.7%) from baseline to first month; 4.8+/-2.9 kg (5.28+/-3.0%) and 5.77+/-2.5 kg (6.17+/-2.9%) from first month to fourth month. Body weight was decreased in groups 1 (P< 0.001) and 2 (P< 0.001), but there was no statistically significant difference between groups. Change of HOMA-IR in groups 1 and 2 was 0.41+/-0.4 (14.9+/-10.1%) and 0.23+/-0.7 (8.16+/-12.3%) from baseline to first month; 0.49+/-0.77 (22.0+/-26%) and 0.95+/-0.88 (34.8+/-29.1%) from first month to fourth month. HOMA-IR value was decreased in groups 1 (P< 0.001) and 2 (P< 0.001) but was not different between groups during the study period.
  
  
  CONCLUSIONS
  Combination of orlistat with metformin did not result in an additional effect on weight loss and insulin resistance when compared to orlistat alone in our study. However, new studies which have more sample sizes and the longer study period are necessary for this purpose.
authors.affiliation: Division of Endocrinology & Metabolism, School of Medicine, Akdeniz University, Turkey. drsari@hotmail.com
authors.forename: R
authors.initials: R
authors.lastname: Sari
authors.forename: M K
authors.initials: MK
authors.lastname: Balci
authors.forename: E
authors.initials: E
authors.lastname: Coban
authors.forename: G
authors.initials: G
authors.lastname: Yazicioglu
mesh_terms: D000328:Adult; D004041:Dietary Fats / Q000378:metabolism; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D007408:Intestinal Absorption / Q000187:drug effects; D007783:Lactones / Q000008:administration & dosage* / Q000627:therapeutic use; D008049:Lipase / Q000037:antagonists & inhibitors*; D008687:Metformin / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism; D000077403:Orlistat; D011446:Prospective Studies; D018709:Statistics, Nonparametric
chemical_list: D004041:Dietary Fats; D007004:Hypoglycemic Agents; D007783:Lactones; D008687:Metformin; D000077403:Orlistat; D008049:Lipase